OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was bought at an average cost of $10.38 per share, for a total transaction of $51,900.00.
NASDAQ:OPRX opened at $10.13 on Friday. The stock has a market cap of $170.46 million, a PE ratio of 202.60, a P/E/G ratio of 1.50 and a beta of 0.42. OptimizeRx Co. has a 52 week low of $8.92 and a 52 week high of $17.24. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $13.49 and its two-hundred day simple moving average is $14.42.
OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.15). The company had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $7.21 million. OptimizeRx had a negative return on equity of 4.19% and a negative net margin of 5.32%. Sell-side analysts anticipate that OptimizeRx Co. will post 0.2 earnings per share for the current fiscal year.
A number of equities analysts recently commented on the company. ValuEngine raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Wednesday. B. Riley decreased their target price on OptimizeRx from $26.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Zacks Investment Research cut OptimizeRx from a “hold” rating to a “sell” rating in a report on Tuesday, November 5th.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Further Reading: Investing in Blue-Chip Stocks
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.